Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
PRGO$15.78-0.14(-0.88%)Perrigo Announces Quarterly Dividend Perrigo Company plc (NYSE: PRGO), a leading provider of consumer self-care products, today announced that its Board of Directors has approved a...[12:30:00 PM ET]SNLGF$4.14-0.12(-2.82%)San Lorenzo Files Second Amended and Restated Offering Document[12:24:30 PM ET]FAGI$0.00+0.00(+2.63%)Full Alliance Group, Inc. (OTC: FAGI) The Future of Commerce Is Not Just Payments – YAHBEE & YAHIVE — It's Relationships[12:20:12 PM ET]DRTS$13.14-0.21(-1.57%)Alpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock Exchange[12:14:57 PM ET]FAGI$0.00+0.00(+2.63%)Full Alliance Group, Inc. (OTC: FAGI): Its Subsidiary Aquaox Pure Solutions Attracts New Business as Major Co[12:14:23 PM ET]UTMD$68.12-0.72(-1.05%)Utah Medical Products, Inc. Reports Corrected Results of Tender Offer[12:10:00 PM ET]KAI$271.38+5.58(+2.10%)Kadant to Hold Earnings Conference Call on Wednesday, November 4, 2026[12:02:20 PM ET]IPX$17.08+1.48(+9.53%)IperionX Webinar – Investor Update[12:00:00 PM ET]DDOG$261.37-17.04(-6.12%)Datadog Named a Leader in AIOps Platforms Research[12:00:00 PM ET]AGNT$3.93+0.00(+0.13%)Arizona's MHG Commercial Joins eXp Commercial With 18 Advisors and $435 Million in Closed Transactions[12:00:00 PM ET]

RXRX · NASDAQ

Recursion Pharmaceuticals, Inc.

$4.29 -0.06 (-1.38%)

Company overview

Recursion Pharmaceuticals is a clinical-stage biotechnology company that decodes biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company is developing multiple therapeutic candidates: REC-994 is in a Phase IIa clinical trial for cerebral cavernous malformation; REC-2282 for neurofibromatosis type 2; REC-4881 for familial adenomatous polyposis; and REC-3599 in a Phase I trial for GM2 gangliosidosis.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$2.3B
Employees
800
Headquarters
Salt Lake City, UT
Website
recursion.com
CEO
Najat Khan
Listed
April 16, 2021
P/E
-3.58
Dividend yield
0.00%

Company financials

Revenue
$66.3M
Gross profit
-$22.8M
Operating income
-$585M
EBITDA
-$486M
Net income
-$560M
EPS
-$1.20
Total assets
$1.3B
Total debt
$72.4M
Gross margin
-34.44%
Net margin
-844.46%
Earnings yield
-27.91%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

Showing FY 2025

Price chart

2.673.333.984.635.29
RXRX 1D NASDAQ O4.00H4.42L3.99C4.35+0.30 (+7.41%)Vol9.16M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
RXRXRecursion Pharmaceuticals, Inc. Stock news Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards? Zacks Investment Research
RXRXRecursion Pharmaceuticals, Inc. Stock news Recursion Pharmaceuticals (RXRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Zacks Investment Research
RXRXRecursion Pharmaceuticals, Inc. Stock news Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider Zacks Investment Research
RXRXRecursion Pharmaceuticals, Inc. Press release Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3 GlobeNewswire
RXRXRecursion Pharmaceuticals, Inc. Press release Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration GlobeNewswire
RXRXRecursion Pharmaceuticals, Inc. Press release Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock GlobeNewswire
RXRXRecursion Pharmaceuticals, Inc. Press release Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone GlobeNewswire
RXRXRecursion Pharmaceuticals, Inc. Stock news Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note Zacks Investment Research
RXRXRecursion Pharmaceuticals, Inc. Stock news Contrasting Recursion Pharmaceuticals (NASDAQ:RXRX) & Oramed Pharmaceuticals (NASDAQ:ORMP) Defense World
RXRXRecursion Pharmaceuticals, Inc. Stock news Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors Zacks Investment Research
RXRXRecursion Pharmaceuticals, Inc. Stock news Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note Zacks Investment Research
ACHC Stock news Squeeze Watch: 10 Stocks With Over 33% Short Interest Benzinga
RXRXRecursion Pharmaceuticals, Inc. Stock news Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? Zacks Investment Research
RXRXRecursion Pharmaceuticals, Inc. Press release Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion's RNA Foundation Model Business Wire
RXRXRecursion Pharmaceuticals, Inc. Stock news Recursion Pharmaceuticals Highlights AI Drug Platform, FAP Progress at Morgan Stanley Conference MarketBeat
RXRXRecursion Pharmaceuticals, Inc. Stock news Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know Zacks Investment Research
RXRXRecursion Pharmaceuticals, Inc. Stock news Recursion Pharmaceuticals, Inc. (RXRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
RXRXRecursion Pharmaceuticals, Inc. Stock news Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today Zacks Investment Research
RXRXRecursion Pharmaceuticals, Inc. Stock news 2 Beaten-Down Stocks to Avoid Right Now Fool - Investing News
RXRXRecursion Pharmaceuticals, Inc. Stock news Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report? Zacks Investment Research
See more
FAQ

Questions about Recursion Pharmaceuticals, Inc.

What does Recursion Pharmaceuticals, Inc. do?
Recursion Pharmaceuticals is a clinical-stage biotechnology company that decodes biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company is developing multiple therapeutic candidates: REC-994 is in a Phase IIa clinical trial for cerebral cavernous malformation; REC-2282 for neurofibromatosis type 2; REC-4881 for familial adenomatous polyposis; and REC-3599 in a Phase I trial for GM2 gangliosidosis.
What is RXRX's market cap?
Recursion Pharmaceuticals, Inc. (RXRX) is a listed stock with a live quote. The latest market cap on this page is $2.3B.
Where is Recursion Pharmaceuticals, Inc. headquartered?
Recursion Pharmaceuticals, Inc. is headquartered in Salt Lake City, UT.
How do I get RXRX news from the API?
Call GET /v1/news?tickers=RXRX. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does RXRX news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for RXRX, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the RXRX price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs